Announcements Trials
Browse Landscape

Phase

Phase NA 15Phase 3 8Phase 2 4Phase 1 2Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 2Lymphoid 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 277Pain, Postoperative 14Neoplasm Metastasis 12Neoplasms 9Prostatic Neoplasms 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Pain 6Osteoporosis 6Seroma 5Colorectal Neoplasms 5Cardiotoxicity 5Breast Diseases 4Breast Cancer Female 4Neutropenia 3Melanoma 3Mastodynia 3Lymphedema 3Lung Neoplasms 3Head and Neck Neoplasms 3Brain Neoplasms 3Bone Diseases, Metabolic 3Vomiting 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sleep Initiation and Maintenance Disorders 2Skin Diseases 2Obesity 2Neurotoxicity Syndromes 2Multiple Myeloma 2

Interventions

Duration of Therapy 1Aprepitant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Nausea × Breast × Clear all
NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Merck Sharp & Dohme LLC

Phase 4 Completed
866 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡